Use and Sequencing of Novel Treatments in NMIBC

Experts discuss where they are using FDA-approved treatments for bacille Calmette-Guérin (BCG)–unresponsive patients in their practice, how they choose between these treatments, and how these advances have impacted the timing of radical cystectomy for patients.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 3:33

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -3:33

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

Now Viewing

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

Video content above is prompted by the following:

• Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients?
• How have these advances changed the timing of radical cystectomy for patients?

Related Videos

BPH: The Patient Journey

Addressing Remaining Unmet Needs in mCRPC

The DORA Trial

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Clinical Perspectives on Early Use of RAD-ENZ

Treatment Selection for mCRPC

Other Investigational Drug Delivery Systems in NMIBC

Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

The Future of RAD-ENZ Combination Therapy